IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS X LLC, Petitioner,

v.

ANACOR PHARMACEUTICALS, INC., Patent Owner.

Case No. IPR2015-01776 Patent No. 7,582,621

DECLARATION OF HOWARD I. MAIBACH, M.D., PH.D., IN SUPPORT OF PATENT OWNER RESPONSE PURSUANT TO 37 C.F.R. § 42.120



I.	Back	rground	. 5
	A.	Onychomycosis and Its Treatment	. 5
	В.	The Anacor Patents	. 8
		1. The '621 Patent	. 8
II.	Disc	ussion	.9
	À.	Long-Felt Need	0
		1. Oral Treatments1	0
		Laser Treatments, Surgery, Nail Avulsion, and Debridement Are Not Solutions for Onychomycosis Treatment	15
		3. Topical Treatments Available Prior to the Patented Inventions	17
		4. The Need for an Effective Topical Treatment with High Patient Acceptance	21
	B.	Failure of Others	24
	C.	Tavaborole Met the Long-Felt Need for a Safe and Effective Topical Treatment with High Patient Acceptance and Received Praise for its Success in Doing So	27



I, Howard I. Maibach, hereby declare as follows:

- 1. I received B.A. and M.D. degrees at Tulane University, and honorary Ph.D. and M.D. degrees from L'Université de Paris-Sud in Paris, Université Claude Bernard in Lyon, Université de Franche-Comté in Besançon, and the University of Southern Denmark.
- 2. I completed my internship at the William Beaumont Army Hospital in El Paso and on-the-job training in neurology and psychiatry at the Walter Reed Army Hospital in Washington, DC. I then practiced neurology and psychiatry in the U.S. Army. My military service was followed by a residency in dermatology and a National Institutes of Health research fellowship at the University of Pennsylvania Hospital. I joined the faculty at the University of Pennsylvania following my residency and fellowship, and in 1961 moved to the University of California Medical School-San Francisco ("UCSF"), where I am currently a professor.
- 3. On arriving at UCSF, I initiated laboratory and clinical investigation into skin physiology, pharmacology, and toxicology. Our laboratory focuses on penetration of chemicals through skin and, more recently, through nails—in both humans, experimental animals, and in test-tube surrogates of the former (*in vitro* penetration).



- 4. I have been treating patients with dermatological conditions, including onychomycosis, since 1961. One of my first research endeavors involved the use of griseofulvin (the first oral antifungal indicated for treatment of onychomycosis). I have founded several clinics, including a psoriasis clinic in which some patients had fungal disease of the nail.
- 5. From approximately 1962 to 1995, I was the volunteer dermatologist for male prisoners in northern California state prisons. Once a week, I traveled to the California Medical Facility and examined inmate patients. Many of these patients had onychomycosis. During the course of my career, I have treated many hundreds of patients with onychomycosis. In addition to treating patients, I have led and participated in many clinical trials of onychomycosis therapies. I still see patients regularly at UCSF.
- 6. The psoriasis clinic I founded treats patients with psoriasis with and without nail involvement. The clinic offered outpatient treatment of skin diseases, and included a large in-patient service at UCSF. I also founded and acted as chief of the UCSF Patch Test Clinic and an occupational dermatology clinic. I encountered (and continue to encounter) patients with onychomycosis at these clinics.

- 7. Today, I work as a tertiary care consultant. I see onychomycosis patients in that work, too. I also direct laboratory work, including some of the work referred to in this Declaration.
- 8. I have authored and co-authored over one thousand published chapters and articles. I also have authored, co-authored, and edited approximately eighty-five published books, including *Topical Nail Products and Ungual Delivery* with Dr. Narasimha Murthy and the *Handbook of Systemic Drug Treatment in Dermatology* with Dr. Sarah Wakelin and Dr. Clive Archer.
- 9. I have consulted with and performed studies for many pharmaceutical companies in connection with potential treatments for onychomycosis, including the following.
- 10. I performed pre-clinical studies for Novartis—over several years—while that company attempted to develop a topical onychomycosis treatment using a formulation with terbinafine, an oral onychomycosis medication.
- 11. I performed pre-clinical studies for Power Paper Limited, and was a consultant in Power Paper's attempted development of an iontophoretic-based topical antifungal treatment.
- 12. I performed pre-clinical studies and acted as a consultant for Topica in their development of a topical onychomycosis therapy.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

